RxDoctor Payments Data

Brian Cassetta, MD

Internal Medicine · Horseheads, NYNPI 1336116037

Payments from drug & device makers

$1,016in general payments, 2019–2025

Across 45 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$485
  • Pfizer$115
  • Novo Nordisk$101
  • Exact Sciences$99
  • Ascensia Diabetes Care US Inc.$74
  • SPR Therapeutics, Inc$68
  • plus $75 from 3 others

What the payments were for

  • Food & beverage$1,00599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,016 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$183,699
Medicare patients
772
Services billed
3,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$298,386
JardianceEmpagliflozin115$121,564
OzempicSemaglutide79$105,037
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$98,163
XareltoRivaroxaban61$71,916
FarxigaDapagliflozin Propanediol44$53,701
EntrestoSacubitril/Valsartan30$45,490
MounjaroTirzepatide25$39,979
JanuviaSitagliptin Phosphate20$31,186
Breo ElliptaFluticasone/Vilanterol55$29,239
BrilintaTicagrelor24$16,081
MyrbetriqMirabegron24$13,431
Rosuvastatin Calcium740$11,186
ArexvyRsvpref3 Antigen/As01e/Pf33$10,186
Metoprolol Succinate536$9,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$298,386310 claims
Novo NordiskOzempic$101$105,03779 claims
AstraZenecaFarxiga, Brilinta$22$69,78268 claims
Lilly USA, LLCMounjaro$12$39,97925 claims
AbbVieSynthroid$485$5,52784 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Horseheads

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →